Form 4: Werewolf Therapeutics Director, Derek DiRocco, Granted Stock Options

Director Derek DiRocco of Werewolf Therapeutics, Inc. was granted stock options but disclaims beneficial ownership due to an arrangement with RA Capital Management, L.P.

Summary

• On May 24, 2024, Derek DiRocco, a director of Werewolf Therapeutics, Inc., was granted stock options to purchase 17,500 shares of common stock at an exercise price of $4.88.
• The options vest fully on the earlier of the first anniversary of the grant date or the next annual meeting of stockholders, contingent upon continued service as a director.
• DiRocco disclaims beneficial ownership of these options and the underlying common stock because he holds them for the benefit of RA Capital Healthcare Fund, L.P. and RA Capital Nexus Fund II, L.P.
• Any net cash or stock received upon exercise of the options will offset advisory fees owed by these funds to RA Capital Management, L.P.

Sentiment

Score: 6

Explanation: The document is a neutral regulatory filing detailing a stock option grant. The arrangement with RA Capital Management is somewhat unusual but doesn't necessarily indicate positive or negative sentiment.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

This filing is a routine disclosure of stock option grants to a company director, which is a common practice in the biotechnology industry to incentivize and retain key personnel. The arrangement with RA Capital Management, L.P. is less common and indicates a specific agreement regarding advisory fees.

Comparison to Industry Standards

• Stock option grants to directors are a standard practice in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of the options (on the earlier of the first anniversary of the grant date or the next annual meeting) is fairly typical.
• The arrangement where the director holds the options for the benefit of a fund and uses the proceeds to offset advisory fees is less common and suggests a specific agreement between the director, the company, and RA Capital Management, L.P.

Related Party Transactions

• The arrangement between Derek DiRocco, RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., and RA Capital Nexus Fund II, L.P. constitutes a related party transaction, as DiRocco's compensation is indirectly tied to the advisory fees owed by the funds to RA Capital Management.

Stakeholder Impact

• The stock option grant could potentially dilute existing shareholders if the options are exercised.
• The arrangement with RA Capital Management may be of interest to shareholders as it involves the use of stock options to offset advisory fees.

Key Dates